NEWS 2/8/18 https://cannasos.com/news/business/
Post# of 164
(Total Views: 585)
Posted On: 02/14/2018 10:57:03 AM
NEWS 2/8/18
https://cannasos.com/news/business/medican-en...gn=sharing
Medican Enterprises Inc. (MDCN:OTC) is pleased to provide additional information on RBA Pharma Inc. which it holds a 40% equity stake in.
WHAT IS RBA PHARMA’S COMPETITIVE ADVANTAGE?
It’s our know-how in the manufacture of PEG and the application of PEGylation — PEGylation is when you attach a PEG structure to another molecule, an active agent — to produce a polymer matrix. We can PEGylate not just analgesics and antibacterials to make the ideal dressing for wounds but also other therapeutic drugs. That way we can customize the matrix to treat other diseases via the skin. What’s more, we manufacture PEG activated without solvents so there’s no residue. In very concrete terms, we are able to provide activated and bio activated mono methoxy PEG, we can do it fast, and in a very cost-effective way. So, again, the potential is immense.
At RBA Pharma, the discovery upon which our company is built, is pure science. The pure science led to the AADD™ polymer matrix and because AADD™ lends itself to a range of innovative applications, our business is potentially three businesses. Wound treatment…drug delivery systems…and PEGylation.
Business number one is wound management. The potential is exceptional because the need is vast and the market for treating wounds is correspondingly vast. Difficult-to-heal wounds — including burns, lacerations, venous, diabetic and pressure ulcers, or wounds resulting from trauma and surgery including plastic surgery, amputations, carcinomas, and so on — are the world’s number one medical problem in that every year more people — almost 200 million worldwide — require specialized medical attention in this area than in any other field of medicine. Current worldwide sales in wound management are estimated at approaching US$15 billion.
The wound care solutions we are now offering to the medical profession are significant: they are both new and original and they meet a real clinical need. In developing our products we also attach the utmost importance to the feedback we get from doctors and nurses who test and use our products.
Wound care is for us just the beginning: our technology platforms can be adapted to a wide range of new applications. For example, because AADD™ is capable of delivering drugs, they can be delivered in remarkably low biological concentrations that may reduce treatment side effects. This means that our new products have potentially high patient appeal. And high doctor and nurse appeal too.
AADD™ drug delivery of active agents through healthy and wounded skin, PEGylating the therapeutic active agents, and activated PEG manufacturing without solvent: All present an attractive new potential for RBA Pharma, opportunities for rewarding partnering deals — in the shape of service contracts — with leading international pharmaceutical companies to develop and manufacture new AADD™-based drug delivery systems.
In conclusion, RBA Pharma has completed pre-clinical effectiveness trials for burns, and partial- and full-thickness wounds in pigs. Data showed faster and better healing of the wounds than observed with standard products.
Updates will be forthcoming
About Medican Enterprises, Inc.
Our Mission is to lead production, distribution, research & development. Medican seeks to become the world’s largest wholesale supplier of pharmaceutical grade cannabis to the medical marijuana industry. A leader in innovation, quality and variety. Leadership Medican delivers strong operational experience and a significant focus on research and development. Medican is uniquely positioned to capitalize on the market opportunity. Quality and Efficiency Medican produces effective Cannabis strains with standardized potency and verified purity. The company has the highest standards of safety and inspection in all areas of quality control, cultivation, and distribution. A combination of in house Research & Development team's, third party testing which ensures the potency of active ingredients in all products and is free of microbial chemical contaminants. Stringent quality control testing provides lot numbers for precise identification of all products.
For More Information, Ken Williams, CEO | Medican Enterprises, Inc.T: +1.313.703.7873E: investors@medican.enterprises
Official Medican Enterprises Website: http://medican.enterprises
https://cannasos.com/news/business/medican-en...gn=sharing
Medican Enterprises Inc. (MDCN:OTC) is pleased to provide additional information on RBA Pharma Inc. which it holds a 40% equity stake in.
WHAT IS RBA PHARMA’S COMPETITIVE ADVANTAGE?
It’s our know-how in the manufacture of PEG and the application of PEGylation — PEGylation is when you attach a PEG structure to another molecule, an active agent — to produce a polymer matrix. We can PEGylate not just analgesics and antibacterials to make the ideal dressing for wounds but also other therapeutic drugs. That way we can customize the matrix to treat other diseases via the skin. What’s more, we manufacture PEG activated without solvents so there’s no residue. In very concrete terms, we are able to provide activated and bio activated mono methoxy PEG, we can do it fast, and in a very cost-effective way. So, again, the potential is immense.
At RBA Pharma, the discovery upon which our company is built, is pure science. The pure science led to the AADD™ polymer matrix and because AADD™ lends itself to a range of innovative applications, our business is potentially three businesses. Wound treatment…drug delivery systems…and PEGylation.
Business number one is wound management. The potential is exceptional because the need is vast and the market for treating wounds is correspondingly vast. Difficult-to-heal wounds — including burns, lacerations, venous, diabetic and pressure ulcers, or wounds resulting from trauma and surgery including plastic surgery, amputations, carcinomas, and so on — are the world’s number one medical problem in that every year more people — almost 200 million worldwide — require specialized medical attention in this area than in any other field of medicine. Current worldwide sales in wound management are estimated at approaching US$15 billion.
The wound care solutions we are now offering to the medical profession are significant: they are both new and original and they meet a real clinical need. In developing our products we also attach the utmost importance to the feedback we get from doctors and nurses who test and use our products.
Wound care is for us just the beginning: our technology platforms can be adapted to a wide range of new applications. For example, because AADD™ is capable of delivering drugs, they can be delivered in remarkably low biological concentrations that may reduce treatment side effects. This means that our new products have potentially high patient appeal. And high doctor and nurse appeal too.
AADD™ drug delivery of active agents through healthy and wounded skin, PEGylating the therapeutic active agents, and activated PEG manufacturing without solvent: All present an attractive new potential for RBA Pharma, opportunities for rewarding partnering deals — in the shape of service contracts — with leading international pharmaceutical companies to develop and manufacture new AADD™-based drug delivery systems.
In conclusion, RBA Pharma has completed pre-clinical effectiveness trials for burns, and partial- and full-thickness wounds in pigs. Data showed faster and better healing of the wounds than observed with standard products.
Updates will be forthcoming
About Medican Enterprises, Inc.
Our Mission is to lead production, distribution, research & development. Medican seeks to become the world’s largest wholesale supplier of pharmaceutical grade cannabis to the medical marijuana industry. A leader in innovation, quality and variety. Leadership Medican delivers strong operational experience and a significant focus on research and development. Medican is uniquely positioned to capitalize on the market opportunity. Quality and Efficiency Medican produces effective Cannabis strains with standardized potency and verified purity. The company has the highest standards of safety and inspection in all areas of quality control, cultivation, and distribution. A combination of in house Research & Development team's, third party testing which ensures the potency of active ingredients in all products and is free of microbial chemical contaminants. Stringent quality control testing provides lot numbers for precise identification of all products.
For More Information, Ken Williams, CEO | Medican Enterprises, Inc.T: +1.313.703.7873E: investors@medican.enterprises
Official Medican Enterprises Website: http://medican.enterprises
(0)
(0)Medican Enterprises Inc (MDCN) Stock Research Links
Disclaimer:
There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator.
Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.
There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in all and any posts.
My posts are NOT investment advice. I am not paid to post.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator.
Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.
There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in all and any posts.
My posts are NOT investment advice. I am not paid to post.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
Scroll down for more posts ▼